Department of Biochemistry, Faculty of Science, King Abdulaziz University (KAU), Jeddah, Saudi Arabia.
Vitamin D Pharmacogenomics Research Group, King Abdulaziz University (KAU), Jeddah, 23623, Saudi Arabia.
Environ Sci Pollut Res Int. 2023 Mar;30(12):33942-33948. doi: 10.1007/s11356-022-24568-3. Epub 2022 Dec 11.
The protein glycation due to high blood glucose mediate release of inflammatory intermediate contributes in the development of diabetic nephropathy. Ferulic acid (FA) is a phenolic compound distributed in different foods as whole grains. Inhibitors of DPP4 improve GLP-1-mediated insulin secretion and inhibit liver gluconeogenesis. This study investigated the impact of FA as anti-inflammatory, antioxidant and antiglycation against streptozotocin-induced diabetic nephropathy in rats. This study was carried out on total ninety male rats allocated into six (each 15 rats); group I (control). All other animals (groups II-VI) were receiving 65 mg/kg STZ for induction of diabetes. Rats in group II (untreated diabetic). Rats in groups III-V were treated with FA (10, 20, 30 mg/kg bw) respectively, i.p. for 8 weeks. Group VI received 10 units insulin daily, sc. Fasting blood samples were subjected for assay of glycated hemoglobin (HA1c), serum MDA, aldose reductase, total antioxidant, DPP4 while kidney tissue subjected for assay of malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), IL-1β and AGEs. Data obtained showed that, FA showed antioxidant activity by reducing MDA and enhancement antioxidant activity compared with untreated rats (p < 0.001) with dose dependence. In addition, FA reduced the activities of aldose reductase, DPP4 (p < 0.001), decreased IL-6, TNF-α and AGEs versus untreated rats (p < 0.001). Histological investigation revealed an improvement in the nephron structure in diabetic rat treated with FA versus untreated group. It was concluded that, FA possesses a potent antioxidant and anti-inflammatory and DPP4 inhibitor. For that, it was considered as a protective agent against the risk of diabetic nephropathy and can be used as alternative or complementary supplement.
由于高血糖导致的蛋白质糖化作用介导了炎症中间产物的释放,从而促进了糖尿病肾病的发生。阿魏酸(FA)是一种酚类化合物,分布在全谷物等不同食物中。DPP4 抑制剂可改善 GLP-1 介导的胰岛素分泌并抑制肝脏糖异生。本研究旨在探讨 FA 作为一种抗炎、抗氧化和抗糖化剂,对链脲佐菌素诱导的糖尿病大鼠肾病的影响。本研究共纳入 90 只雄性大鼠,随机分为 6 组(每组 15 只):I 组(对照组)。其余所有动物(II-VI 组)均接受 65mg/kg STZ 诱导糖尿病。II 组(未治疗的糖尿病组)为未治疗的糖尿病大鼠。III-VI 组大鼠分别腹腔注射 FA(10、20、30mg/kg bw),连续 8 周。VI 组每日接受 10 单位胰岛素皮下注射。采集空腹血样,检测糖化血红蛋白(HA1c)、血清 MDA、醛糖还原酶、总抗氧化剂、DPP4,肾组织检测丙二醛(MDA)、还原型谷胱甘肽(GSH)、过氧化氢酶(CAT)、超氧化物歧化酶(SOD)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和 AGEs。结果显示,FA 具有抗氧化活性,可降低 MDA 并增强抗氧化活性,与未治疗的糖尿病大鼠相比差异有统计学意义(p<0.001),且呈剂量依赖性。此外,FA 降低了醛糖还原酶和 DPP4 的活性(p<0.001),降低了 IL-6、TNF-α 和 AGEs 的水平,与未治疗的糖尿病大鼠相比差异有统计学意义(p<0.001)。组织学检查显示,FA 治疗的糖尿病大鼠的肾单位结构得到改善,与未治疗组相比差异有统计学意义。综上所述,FA 具有较强的抗氧化、抗炎和 DPP4 抑制作用。因此,FA 可作为糖尿病肾病发生风险的保护剂,可作为替代或补充治疗。